These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 1995092)

  • 1. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.
    Stevenson FK; Bell AJ; Cusack R; Hamblin TJ; Slade CJ; Spellerberg MB; Stevenson GT
    Blood; 1991 Mar; 77(5):1071-9. PubMed ID: 1995092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma.
    Ellis JH; Barber KA; Tutt A; Hale C; Lewis AP; Glennie MJ; Stevenson GT; Crowe JS
    J Immunol; 1995 Jul; 155(2):925-37. PubMed ID: 7608568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma.
    Goldmacher VS; Bourret LA; Levine BA; Rasmussen RA; Pourshadi M; Lambert JM; Anderson KC
    Blood; 1994 Nov; 84(9):3017-25. PubMed ID: 7524764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1.
    Hata H; Matsuzaki H; Matsuno F; Sonoki T; Takemoto S; Kuribayashi N; Nagasaki A; Takatsuki K
    Clin Exp Immunol; 1994 May; 96(2):370-5. PubMed ID: 8187346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells.
    Yi Q; Dabadghao S; Osterborg A; Bergenbrant S; Holm G
    Blood; 1997 Sep; 90(5):1960-7. PubMed ID: 9292530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma.
    Kimlinger T; Witzig TE
    Bone Marrow Transplant; 1997 Mar; 19(6):553-6. PubMed ID: 9085734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of CD38 as target for immunotherapy in multiple myeloma.
    Vooijs WC; Schuurman HJ; Bast EJ; de Gast GC
    Blood; 1995 Apr; 85(8):2282-4. PubMed ID: 7718903
    [No Abstract]   [Full Text] [Related]  

  • 9. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells.
    Terstappen LW; Huang S; Safford M; Lansdorp PM; Loken MR
    Blood; 1991 Mar; 77(6):1218-27. PubMed ID: 1705833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance.
    van de Donk NWCJ; Usmani SZ
    Front Immunol; 2018; 9():2134. PubMed ID: 30294326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
    Edri A; Ben-Haim N; Hailu A; Brycman N; Berhani-Zipori O; Rifman J; Cohen S; Yackoubov D; Rosenberg M; Simantov R; Teru H; Kurata K; Anderson KC; Hendel A; Pato A; Geffen Y
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulatory effects of CD38-targeting antibodies.
    van de Donk NWCJ
    Immunol Lett; 2018 Jul; 199():16-22. PubMed ID: 29702148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry.
    Terstappen LW; Johnsen S; Segers-Nolten IM; Loken MR
    Blood; 1990 Nov; 76(9):1739-47. PubMed ID: 2224123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.
    Ozaki S; Kosaka M; Wakahara Y; Ozaki Y; Tsuchiya M; Koishihara Y; Goto T; Matsumoto T
    Blood; 1999 Jun; 93(11):3922-30. PubMed ID: 10339501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of early plasma cells in peripheral blood and their clinical significance.
    Harada Y; Kawano MM; Huang N; Mahmoud MS; Lisukov IA; Mihara K; Tsujimoto T; Kuramoto A
    Br J Haematol; 1996 Jan; 92(1):184-91. PubMed ID: 8562394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD38-Specific Biparatopic Heavy Chain Antibodies Display Potent Complement-Dependent Cytotoxicity Against Multiple Myeloma Cells.
    Schütze K; Petry K; Hambach J; Schuster N; Fumey W; Schriewer L; Röckendorf J; Menzel S; Albrecht B; Haag F; Stortelers C; Bannas P; Koch-Nolte F
    Front Immunol; 2018; 9():2553. PubMed ID: 30524421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional differences between CD38- and DR- subfractions of CD34+ bone marrow cells.
    Rusten LS; Jacobsen SE; Kaalhus O; Veiby OP; Funderud S; Smeland EB
    Blood; 1994 Sep; 84(5):1473-81. PubMed ID: 7520773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CD38 antibodies in multiple myeloma].
    Moreaux J
    Med Sci (Paris); 2019 Dec; 35(12):1001-1004. PubMed ID: 31903907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multi-faceted potential of CD38 antibody targeting in multiple myeloma.
    Shallis RM; Terry CM; Lim SH
    Cancer Immunol Immunother; 2017 Jun; 66(6):697-703. PubMed ID: 28341874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.